#Paris #France #Echosens #FibroScan #Romain Baujard

Echosens Welcomes Romain Baujard as New CEO

Echosens, an international leader in non-invasive diagnostic devices and services, has announced the appointment of Romain Baujard as the new Group Chief Executive Officer effective May 1, 2026. His promotion comes as Dominique Legros retires after successfully leading the company since 2019. Under Legros’ stewardship, Echosens has seen significant global expansion and increased adoption of its innovative technologies.

At Echosens, Baujard will support the company's mission: to position liver health as a crucial indicator in the assessments of cardiometabolic care. Supported by Inner Mongolia FuRui Medical Science, a high-tech healthcare company focused on liver disease, and Astorg, a leading European private equity firm with substantial health sector experience, Echosens aims for a new growth phase with an emphasis on integrating liver health into broader health evaluations and treatments.

Romain Baujard joined Echosens in 2015, serving most recently as Vice President of Pharma. He has held various strategic and operational roles, including global marketing and international business operations. His ability to forge global partnerships with leading pharmaceutical companies has significantly strengthened Echosens' position in the intersection of liver health and emerging cardiometabolic therapies, an area garnering increasing clinical attention and investment.

Baujard expressed excitement over his new role: “I am honored to take on this responsibility as Echosens stands at a crucial juncture with innovation accelerating in cardiometabolic care. Liver evaluation is becoming essential for comprehensive patient assessments. We have the chance to integrate liver evaluation into routine care at scale.” He further emphasized his commitment to broadening access to their technologies, supporting clinicians, and leveraging advancements in digital capabilities, data, and AI for enhanced early detection and efficient risk management.

Since taking the helm in 2019, Dominique Legros has navigated Echosens through a dynamic period of growth and transformation, reaffirming its position as a global standard in non-invasive liver assessment. Under his direction, FibroScan® has expanded its applications beyond hepatology and gastroenterology, reaching into diabetes, endocrinology, and primary care areas. This shift highlights the growing recognition of liver health as a key factor in broader metabolic management and the growing opportunities within underserved patient populations.

Reflecting on his tenure, Legros stated: “Leading Echosens has been a privilege. Our mission has always been to empower healthcare professionals to make better-informed decisions, ultimately improving patient outcomes. Liver health is critical, and I am proud of what our teams have achieved in advocating this message across global care pathways. I am confident that Romain is the right leader to guide Echosens into its next phase of growth.”

Echosens shareholders, alongside Laurent Sandrin, president and co-founder, acknowledged the robust foundation built under Legros’ leadership, illustrated by growing clinical adoption and a global outreach strategy. They expressed gratitude for his significant contributions to developing the company. “We have worked closely with Romain for many years, witnessing his remarkable results as he took on increasingly responsible roles within the organization.”

About Echosens
Echosens is a frontrunner in non-invasive solutions for assessing liver health. With its FibroScan® technology and an expanding digital ecosystem, the company is dedicated to making liver health a vital sign in cardiometabolic care, emphasizing the importance of liver health in patient care.

About Inner Mongolia FuRui Medical Science Co.
Founded in 1998 and based in Beijing, Inner Mongolia FuRui Medical Science aims to prevent, diagnose, treat, and manage long-term liver diseases with a mission to “keep every family away from liver cancer.” Listed on the Shenzhen Stock Exchange (300049), the company utilizes an integrated care management model combining non-invasive diagnostics, pharmaceutical therapies, digital health services, and insurance solutions.

About Astorg
Astorg, a leading European private equity firm, manages over €23 billion in assets. The firm collaborates with entrepreneurs and management teams to acquire market-leading international companies based in Europe or the United States, providing strategic direction, governance, and capital to achieve growth objectives. The firm distinguishes itself with a unique entrepreneurial culture and long-term shareholder perspective, possessing valuable sector expertise in health, technology, and software.

Founded in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan. For more information, visit Astorg’s website.

Photo and Logo:
Image of Romain Baujard